Clinical trials: Neoadjuvant Immunochemotherapy
Non-small Cell Lung Cancer
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable…
- Trial name
- neoSCORE (NCT04459611)
- Testing
- sintilimab, pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
This is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell…
- Trial name
- HCHTOG2603 (NCT07629817)
- Testing
- Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy, Radiation with Concurrent Chemotherapy, Radical Esophagectomy
- Where
- China
- Volunteers
- 1,044 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer, Surgery
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown.
- Conditions
- Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
- Trial name
- NCT04280822
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Esophageal Cancer
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
We intend to conduct a prospective single-arm clinical study to explore the efficacy and safety of immunochemotherapy in neoadjuvant therapy in elderly patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06403878
- Testing
- Carboplatin, Nab paclitaxel, Sintilimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sichuan University
Carcinoma, Non-Small-Cell Lung
SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer
The purpose of this study is to find out the effectiveness stereotactic body radiation therapy (SBRT) followed by two cycles of Tislelizumab (PD-1 inhibitor) with chemotherapy as treatment for operable stage II to III non-small…
- Trial name
- SACTION01 (NCT05319574)
- Testing
- SBRT, Tislelizumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
Real-world Analysis on the Efficacy and Safety of Neoadjuvant Therapy for Head and Neck Squamous Cell Carcinoma （neoHNSCC）
This is a retrospective, single-arm study that assesses the efficacy and safety of neoadjuvant immunotherapy combined with platinum-based chemotherapy for Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT06011993
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Squamous Cell Carcinoma (ESCC)
TDLN-Guided Lymphadenectomy After Neoadjuvant Immunochemotherapy for ESCC
This is a prospective, multicenter, observational cohort study of patients with esophageal squamous cell carcinoma who have received neoadjuvant immunochemotherapy and are scheduled to undergo curative esophagectomy with standard…
- Trial name
- NCT07697898
- Testing
- Curative Esophagectomy With Systematic Lymphadenectomy
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
Esophageal Cancer
The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer
Treatment with immune checkpoint inhibitors such as programmed death receptor 1 (PD-1 inhibitors) for advanced and metastatic esophageal squamous cell carcinoma (ESCC) significantly improves patients' overall survival compared to…
- Trial name
- POSITRON (NCT05615103)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangdong Provincial People's Hospital
Colon Cancer, PCSK9 Inhibitor
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally…
- Conditions
- Colon Cancer, PCSK9 Inhibitor, Neoadjuvant Immunochemotherapy
- Trial name
- TRIUNITE-08 (NCT07840677)
- Testing
- Tafolecimab, Sintilimab
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Gastric Cancer (GC)
Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric Cancer
Study Population: Patients with locally advanced gastric cancer complicated by primary hypertension, who received neoadjuvant immunochemotherapy followed by curative gastrectomy at Nanfang Hospital of Southern Medical University…
- Trial name
- BNIHGC (NCT07622693)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Cervical Cancers
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of paclitaxel and carboplatin combined with PD-1/PD-L1 immune checkpoint inhibitors in the treatment of locally advanced…
- Trial name
- NCT07003620
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NSCLC
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
This study is a prospective, randomized controlled multicenter clinical trial. The study population consisted of non-small cell lung cancer（NSCLC） patients in stage IIA-IIIB (IASLC 9th edition) who received immunotherapy combined…
- Trial name
- NCT07612722
- Testing
- Sub-lobectomy, Lobectomy
- Where
- China
- Volunteers
- 585 people
- Sponsor
- Wen-zhao ZHONG
Esophageal Squamous Cell Carcinoma
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06446726
- Testing
- Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Follicular Lymphoma, Marginal Zone Lymphoma
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.
Evaluation of event free survival (EFS) of patients treated with the study chemotherapy induction program: R-CHOP compared to the standard R-CVP regimen and response rates, time to best response, PFS, OS, neutropenic fever rate…
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
- Trial name
- PLRG4 (NCT00801281)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin
- Where
- 12 sites in Poland
- Volunteers
- 250 people
- Sponsor
- Polish Lymphoma Research Group
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China, with most patients presenting with locally advanced disease.
- Trial name
- TTE-ESCC (NCT07778056)
- Testing
- Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Colon Adenocarcinoma
HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer
The purpose of this clinical trial is to learn the safety and efficacy of HDAC inhibitors in combination with neoadjuvant immunochemotherapy compared to neoadjuvant therapy in the treatment of locally advanced colon cancer.
- Trial name
- NCT06709885
- Testing
- Chidamide + Tislelizumab + chemotherapy (CapeOX ), CapeOX
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University